IP Library Granted Patent US 7,524,275
Granted Patent B2
US 7,524,275 · App. 10/714,586 · Granted Apr 28, 2009

Drug eluting brachytherapy methods and apparatus

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,524,275
App. No.
10/714,586
Granted
Apr 28, 2009
Kind
B2
Abstract

An interstitial brachytherapy apparatus and methods for treating proliferative tissue disorders with radiation and a surface delivered treatment agent. The brachytherapy device includes an insertion member having proximal and distal portions and at least one lumen extending therethrough. An expandable surface member is mated to the distal portion of the insertion member and includes a treatment agent releasably mated thereon. When the brachytherapy device is positioned within a tissue cavity and the expandable surface member is expanded, at least a portion of the treatment agent is delivered to tissue surrounding the tissue cavity.

Claims (37)

1. A drug eluting brachytherapy device, comprising:

(a) an insertion member having a proximal portion, a distal portion, and at least one lumen extending therethrough:

(b) an expandable surface member mated to the distal portion of the insertion member and defining a spatial volume therein, wherein said spatial volume is configured to receive a radiation source therein to enable a three-dimensional isodose profile that is substantially similar in shape to said expandable surface member; and

(c) a plurality of treatment releasably mated with an outer surface of the expandable surface member; wherein at least a portion of each of the treatment agents is delivered to adjacent tissue when the brachytherapy device is positioned within a tissue cavity, and wherein a first treatment agent begins delivery before a second treatment agent.

2. The device of claim 1 , wherein the expandable surface member is a fluid retaining expandable surface member.

3. The device of claim 1 , wherein at least one treatment agent is nonradioactive.

4. The device of claim 1 , wherein the treatment agents are coated on the outer surface of the expandable surface member.

5. The device of claim 4 , wherein different treatment agents are disposed in different layers.

6. The device of claim 1 , wherein at least one treatment agent is dispersed within a sidewall of the expandable surface member.

7. The device of claim 1 , wherein at least one treatment agent is disposed on only a portion of the surface of the expandable surface member.

8. The device of claim 7 , wherein the at least one treatment agent is disposed on less then about half the surface of the expandable surface member.

9. The device of claim 1 , wherein the expandable surface member includes a first surface adapted for positioning against a tissue surface.

10. The device of claim 9 , wherein at least one treatment agent is disposed only on the first surface.

11. The device of claim 1 , wherein each treatment agent is selected from the group consisting of, a chemotherapy drug, an anti-neoplastic agent, an anti-angiogenesis agent, an immunomodulator, a hormonal agent, an immunotherapeutic agent, a pain reliever, an antibiotic or combinations thereof.

12. The device of claim 1 , wherein at least one of the treatment agents is mixed with a binding agent.

13. The device of claim 12 , wherein the binding agent is a bioresorbable polymeric binding agent.

14. A drug eluting tissue positioning device for positioning target tissue surrounding a resected tissue cavity so that the target tissue can receive a measured radiation dose, comprising:

a catheter body member having a proximal portion and a distal portion;

an expandable surface member, the expandable surface member defining a spatial volume therein, wherein said spatial volume is configured to receive a radiation source therein; and

a plurality of treatment releasably mated with an outer surface of the expandable surface member; wherein at least a portion of each treatment agent is delivered to tissue surrounding the resected tissue cavity when the device is positioned within the resected tissue cavity, and wherein a first treatment agent begins deliver to the tissue before a second treatment agent begins delivery.

15. The device of claim 14 , wherein the expandable surface member is constructed of a material permeable to a treatment agent.

16. The device of claim 15 , wherein a third treatment agent capable of permeating through the walls of the expandable surface member is disposed within the expandable surface member.

17. The device of claim 16 , wherein a fluid delivery path for the delivery of the third treatment agent extends through the catheter body member into the spatial volume within the expandable surface member, and out through the permeable expandable surface member.

18. The device of claim 14 , wherein the expandable surface member includes permeable and nonpermeable portions, and the treatment agents are mated with only the nonpermeable portions.

19. The device of claim 14 , wherein each treatment agent is selected from the group consisting of, a chemotherapy drug, an anti-neoplastic agent, an anti-angiogenesis agent, an immunomodulator, a hormonal agent, an immunotherapeutic agent, an antibiotic or combinations thereof.

20. The device of claim 14 , wherein a radiation source is disposed within the expandable surface member.

21. The device of claim 14 , wherein an external radiation source is disposed outside of the expandable surface member.

22. A method of delivering a treatment material, comprising:

providing a drug eluting brachytherapy device having a catheter body member with a proximal portion and a distal portion, an expandable surface member defining a spatial volume, and a plurality treatment agents releasably mated with an outer surface of the expandable surface member;

positioning the brachytherapy device within a tissue cavity; and

delivering the treatment agents to tissue surrounding the tissue cavity, wherein a first treatment agent begins releasing before a second treatment agent begins releasing.

23. The method of claim 22 , wherein the tissue cavity is a resected tissue cavity created during a lumpectomy procedure.

24. The method of claim 22 , wherein at least one treatment agent is a chemotherapy drug.

25. The method of claim 22 , wherein the plurality of treatment agents are layered on the outer surface of the expandable surface member and the first treatment agent is disposed in an outer layer and the second treatment agent is disposed in an inner layer.

26. The method of claim 22 , wherein the tissue cavity is a naturally occurring cavity.

27. The method of claim 26 , wherein the cavity is selected from the group consisting of the bladder, the esophagus, the gut, the urethra, and the ureters.

28. The method of claim 22 , wherein the tissue cavity is mechanically formed.

Assignments (12)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS Recorded Aug 25, 2010
From: GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT
To: HOLOGIC, INC.; R2 TECHNOLOGY, INC.; SUROS SURGICAL SYSTEMS, INC.; BIOLUCENT, LLC; DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS LIMITED PARTNERSHIP; CYTYC SURGICAL PRODUCTS II LIMITED PARTNERSHIP; CYTYC SURGICAL PRODUCTS III, INC.; CYTYC PRENATAL PRODUCTS CORP.; THIRD WAVE TECHNOLOGIES, INC.
Reel/Frame 024944/0315 →
PATENT SECURITY AGREEMENT Recorded Jul 29, 2008
From: CYTYC CORPORATION
To: GOLDMAN SACHS CREDIT PARTNERS L.P., AS COLLATERAL AGENT
Reel/Frame 021301/0879 →
PATENT SECURITY AGREEMENT Recorded Oct 26, 2007
From: CYTYC CORPORATION
To: GOLDMAN SACHS CREDIT PARTNERS L.P.
Reel/Frame 020018/0529 →
MERGER Recorded Nov 21, 2005
From: PROXIMA THEREAPEUTICS, INC.
To: CYTYC CORPORATION
Reel/Frame 017251/0131 →
MERGER, CHANGE OF NAME AND CHANGE OF STATE OF INCORPORATION Recorded Dec 15, 2004
From: PROXIMA THERAPEUTICS, INC. (A MINNESOTA CORPORATION) MERGED WITH AND INTO PTI OF DELAWARE, INC. ( A DELAWARE CORPORATION)
To: PROXIMA THERAPEUTICS, INC.
Reel/Frame 016069/0893 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2004
From: PATRICK, TIMOTHY J.; STUBBS, JAMES B.
To: PROXIMA THERAPEUTICS, INC.
Reel/Frame 015046/0104 →